Regulus Therapeutics (RGLS) Reports In-Line Q3 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.40), in-line with the analyst estimate of ($0.40).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
• Worried the AI trade has gone too far? Evercore likes these 4 stocks